Anthony Sung

Overview:

I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.

Positions:

Associate Professor of Medicine

Medicine, Hematologic Malignancies and Cellular Therapy
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Senior Fellow in the Center for the Study of Aging and Human Development

Center for the Study of Aging and Human Development
School of Medicine

Education:

M.D. 2008

Harvard University

Residency, Osler Medical Housestaff Training Program

Johns Hopkins University School of Medicine

Fellowship, Hematology Oncology

Duke University School of Medicine

Grants:

Patient-centered home-based hematopoietic stem cell transplantation

Administered By
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease

Administered By
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Keratinocyte targeted strategies for treatment of cutaneous GVHD

Administered By
Dermatology
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Mitigators of Radiation-Induced Endovascular Injury: Targeting Tie2 and Thrombocytopenia

Administered By
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

Home Transplant to Preserve the Microbiota and Decrease GVHD

Administered By
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
American Society of Hematology
Role
Principal Investigator
Start Date
End Date

Publications:

eHealth-Generated Patient Data in an Outpatient Setting after Hematopoietic Stem Cell Transplantation: A Scoping Review.

Hematopoietic stem cell transplantation (HCT) has the potential to cure malignant and nonmalignant diseases but remains associated with a wide range of complications, necessitating dedicated lifelong follow-up. While patients are monitored closely during the peri-HCT period, leaving the hospital setting after HCT introduces new challenges. This scoping review explores the current use of patient-generated eHealth data in the outpatient setting. A systematic search of the PubMed, Scopus, Cumulative Index to Nursing and Allied Health Literature, American Psychological Association PsycINFO, and International Health Technology Assessment databases in July 2021 identified the 22 studies (13 full text articles and 9 abstracts) included in this review. The large majority were small to medium-sized (n = 15; 68.2%) pilot or feasibility studies (n = 18; 81.8%) that were published between 2016 and 2021 (n = 16; 72.7%). Collection of patient-reported outcomes was the most frequently reported eHealth intervention (n = 14; 63.6%), followed by vital sign monitoring (n = 5; 22.7%) and home-based spirometry (n = 3; 13.6%), mostly in the early post-transplantation setting. eHealth interventions had favorable feasibility and acceptability profiles; however, we found little data on the efficacy, long-term monitoring, data security, and cost-effectiveness of eHealth interventions. Larger randomized studies are warranted to draw formal conclusions about the impact of eHealth on HCT outcomes and the best ways to incorporate eHealth in clinical practice.
Authors
Van Opstal, J; Zhao, AT; Kaplan, SJ; Sung, AD; Schoemans, H
MLA Citation
Van Opstal, Jolien, et al. “eHealth-Generated Patient Data in an Outpatient Setting after Hematopoietic Stem Cell Transplantation: A Scoping Review.Transplant Cell Ther, vol. 28, no. 8, Aug. 2022, pp. 463–71. Pubmed, doi:10.1016/j.jtct.2022.05.016.
URI
https://scholars.duke.edu/individual/pub1529362
PMID
35589058
Source
pubmed
Published In
Transplant Cell Ther
Volume
28
Published Date
Start Page
463
End Page
471
DOI
10.1016/j.jtct.2022.05.016

Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.

PURPOSE OF REVIEW: Recent medical advances have allowed a greater number of older patients to undergo hematopoietic stem cell transplantation (HSCT) and participate in HSCT trials. In this review, we outline recent advances in HSCT that have made this possible, general setbacks, and their effects on the landscape of HSCT trials in older adults. RECENT FINDINGS: Reduced-intensity conditioning regimens and a more physiological approach to transplant candidate selection have given older patients an opportunity to participate in HSCT trials. However, difficulties in allogeneic donor selection, post-transplant complications, and the misalignment of trial goals with patient goals may pose challenges for future trial recruitment and success. While increasing amounts of evidence show that older adults may benefit from participation in HSCT trials, clinicians, investigators, and patients must carefully weigh the benefits with potential repercussions.
Authors
Zhao, AT; Sung, AD
MLA Citation
Zhao, Aaron T., and Anthony D. Sung. “Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.Curr Oncol Rep, vol. 24, no. 1, Jan. 2022, pp. 125–33. Pubmed, doi:10.1007/s11912-022-01194-3.
URI
https://scholars.duke.edu/individual/pub1507552
PMID
35061190
Source
pubmed
Published In
Current Oncology Reports
Volume
24
Published Date
Start Page
125
End Page
133
DOI
10.1007/s11912-022-01194-3

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.

Authors
Pabon, CM; Li, Z; Hennig, T; de Castro, C; Neff, JL; Horwitz, ME; LeBlanc, TW; Long, GD; Lopez, RD; Sung, AD; Chao, N; Gasparetto, C; Sarantopoulos, S; Adams, DB; Erba, H; Rizzieri, DA
MLA Citation
Pabon, Cindy M., et al. “Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.Blood Cancer Journal, vol. 11, no. 5, May 2021, p. 92. Epmc, doi:10.1038/s41408-021-00481-9.
URI
https://scholars.duke.edu/individual/pub1482850
PMID
33994546
Source
epmc
Published In
Blood Cancer Journal
Volume
11
Published Date
Start Page
92
DOI
10.1038/s41408-021-00481-9

Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol.

INTRODUCTION: The COVID-19 pandemic has proven to be an unprecedented challenge to worldwide health, and strategies to mitigate the spread and severity of COVID-19 infection are urgently needed. Emerging evidence suggests that the composition of the gut microbiome and modification of microbial ecology via probiotics can affect susceptibility to a wide range of infections, including respiratory tract infections. In this study, we aim to evaluate the effects of the probiotic Lactobacillus rhamnosus GG (LGG) versus placebo on COVID-19 infection status and the gut microbiome in subjects with a household contact who has tested positive for COVID-19. METHODS AND ANALYSIS: In this double-blinded, randomised, placebo-controlled trial, we will randomise 1132 subjects having a household contact who has recently (≤7 days) tested positive for COVID-19 to daily oral LGG or placebo for 28 days. We hypothesise that taking LGG as a probiotic will protect against COVID-19 infection and reduce the severity of disease in those who become infected (primary endpoint: decreased symptoms), and will be associated with beneficial changes in the composition of the gut microbiome. Stool samples and nasal swabs will be collected to evaluate the microbiome by 16S rRNA sequencing and the presence of SARS-CoV-2 by PCR, respectively. We will also conduct multivariate analysis of demographic, behavioural, temporal, and other variables that may predict development of symptoms and other outcomes. ETHICS AND DISSEMINATION: This trial is conducted under a Food and Drug Administration Investigational New Drug for LGG, has received ethics approval by the institutional review board of Duke University and enrolment has begun. We plan to disseminate the results in peer-reviewed journals and at national and international conferences. TRIAL REGISTRATION NUMBER: NCT04399252.
Authors
Tang, H; Bohannon, L; Lew, M; Jensen, D; Jung, S-H; Zhao, A; Sung, AD; Wischmeyer, PE
MLA Citation
Tang, Helen, et al. “Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol.Bmj Open, vol. 11, no. 5, May 2021, p. e047069. Pubmed, doi:10.1136/bmjopen-2020-047069.
URI
https://scholars.duke.edu/individual/pub1482275
PMID
33952552
Source
pubmed
Published In
Bmj Open
Volume
11
Published Date
Start Page
e047069
DOI
10.1136/bmjopen-2020-047069

Stem cell transplant and financial toxicity: A single-center prospective cohort analysis.

Authors
Hussaini, S; Ren, Y; Lew, M; Bohannon, L; Thompson, JC; Zafar, Y; Sung, AD
MLA Citation
Hussaini, Syed, et al. “Stem cell transplant and financial toxicity: A single-center prospective cohort analysis.Journal of Clinical Oncology, vol. 38, no. 15, 2020.
URI
https://scholars.duke.edu/individual/pub1475910
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
38
Published Date